Skip to main content

Savings and Affordability

There are no clinically meaningful differences between MERILOG (insulin aspart-szjj) injection 100 Units/mL and Novolog®.

Learn more about the medications available from Sanofi, and how patients can access savings as they get started. Eligibility and restrictions apply.

Check eligibility for savings or help patients sign up to receive educational emails about MERILOG and living with diabetes—powered by TeamingUp.

Patients with commercial/private insurance for prescriptions? (for example from your Employer)

MERILOG insulin co-pay card: Commercially insured patients 'Pay no more than $35' for a 30-day supply. Terms and conditions apply.

With the Sanofi Insulins Co-pay Savings Program, commercially insured patients pay no more than $35* per 30-day supply of Sanofi Insulins.

Patients with no commercial insurance or commercially insured but paying cash for prescriptions?

Insulins Valyou Savings Program logo reading $35 per month and indicating terms and conditions.

With the Insulins Valyou Savings Program, patients pay $35* per 30-day monthly supply of any one or combination of Sanofi Insulins. All insulin prescriptions must be filled at the same time from the pharmacy.

Help your patients get a card

Eligible patients with commercial insurance: Pay no more than $35 for a 30-day supply.*

Help your patients activate a card

Patients can activate their cards or register for a new card.

Get Support

Find out more information at TeamingUp

Take me to support and savings

*See Terms and Eligibility Restrictions

Sanofi Patient Support

Sanofi Patient Support Services helps you get the care and support you need.

*Eligibility Restrictions & Offer Terms:

Sanofi Insulins Co-pay Savings Program: This savings program is not insurance. For a complete list of participating brands, products, and National Drug Codes (NDCs) Click Here. This offer is not valid for prescriptions covered by or submitted for reimbursement, in whole or in part, under Medicare, Medicaid, VA, DOD, TRICARE, similar federal or state programs, including any state pharmaceutical programs. If you have an Affordable Care (Health Care Exchange) plan, you may still be qualified to receive and use this savings card. Please note: the Federal Employees Health Benefits (FEHB) Program is not a federal or state government health care program for purposes of the savings program. Void where prohibited by law. For the duration of the program, eligible commercially insured patients pay no more than $35 per 30-day supply, up to 10 packs per fill; Offer valid for one fill every 30 days. Savings may vary depending on patients’ out-of-pocket costs. There are other relevant costs associated with overall treatment. Sanofi reserves the right to rescind, revoke, terminate, or amend this offer, eligibility, and terms of use at any time without notice. Upon registration, patients will receive all program details. For questions regarding your eligibility or benefits, or if you wish to discontinue your participation, call the Sanofi Insulins Co-pay Savings Program at (866) 255-8661 (8:00 am-8:00 pm EST, Monday-Friday).

Insulins Valyou Savings Program: This savings program is not insurance. For a complete list of participating brands, products, and National Drug Codes (NDCs) Click Here. This offer is only valid for those who are uninsured or those who are insured by a prescription plan but are not using such insurance and will be paying the full retail price for the medication. Void where prohibited by law. For the duration of the program, eligible patients will pay $35 per 30-day supply. To pay $35 per 30-day supply, you must fill all your Sanofi Insulin prescriptions at the same time, together each month. The Savings Program applies to the cost of medication. There are other relevant costs associated with overall treatment. You may not submit claims for reimbursement to any third-party payor, including any government healthcare plan (e.g., Medicare, Medicaid, DOD, VA, TRICARE) or similar federal or state programs for Sanofi Insulin prescriptions when using this Program. You may not seek to have your out-of-pocket costs or the full retail price of the Sanofi Insulin count toward your deductible, true-out-of-pocket (TrOOP), maximum out-of-pocket (MOOP), or any other out-of-pocket caps associated with any insurance coverage. Sanofi reserves the right to rescind, revoke, terminate, or amend this offer, eligibility, and terms of use at any time without notice. Upon registration, patients will receive all program details. For questions regarding your eligibility or benefits, or if you wish to discontinue your participation, call the Insulins Valyou Savings Program at (833) 813-0190 (8:00 am-8:00 pm EST, Monday-Friday).

Important Safety Information

Contraindications 
MERILOG is contraindicated during episodes of hypoglycemia and in patients with hypersensitivity to insulin aspart products or any of the excipients in MERILOG.

Warnings and Precautions
Never share a MERILOG SoloStar® prefilled pen between patients, even if the needle is changed: Sharing poses a risk for transmission of blood-borne pathogens. 

Make changes to a patient’s insulin regimen (e.g., insulin strength, manufacturer, type, injection site or method of administration) under close medical supervision with increased frequency of blood glucose monitoring. Changes in insulin regimen may affect glycemic control and predispose to hyperglycemia or hypoglycemia. Repeated insulin injections into areas of lipodystrophy or localized cutaneous amyloidosis may result in hyperglycemia; sudden change in the injection site (to unaffected area) has been reported to result in hypoglycemia. Advise patients to rotate injection site to unaffected areas and closely monitor for hypoglycemia. 

Hypoglycemia is the most common adverse reaction associated with insulins, including MERILOG and may be life-threatening. 

Accidental mix-ups between basal insulin products and other insulins, particularly rapid-acting insulins, have been reported. To avoid medication errors between MERILOG and other insulins, instruct patients to always check the insulin label before each injection. 

Severe, life-threatening, generalized allergy, including anaphylaxis, can occur with insulin products, including MERILOG. If hypersensitivity reactions occur, discontinue MERILOG, treat per standard of care and monitor until symptoms and signs resolve. 

All insulin products, including MERILOG, can cause hypokalemia. Untreated hypokalemia may cause respiratory paralysis, ventricular arrhythmia, and death. Monitor potassium levels in patients at risk for hypokalemia. 

Fluid retention and heart failure can occur with concomitant use of thiazolidinediones (TZDs) which are peroxisome proliferator-activated receptor (PPAR)-gamma agonists, and particularly when used with insulin. Observe for signs and symptoms of heart failure. Consider dosage reduction or discontinuation of TZD if heart failure occurs. 

Adverse Reactions
Adverse reactions observed with insulin aspart products include hypoglycemia, allergic reactions, local injection site reactions, lipodystrophy, rash, and pruritus. 

Drug Interactions
Certain drugs may affect glucose metabolism, requiring insulin dose adjustment and close monitoring of blood glucose. The signs of hypoglycemia may be reduced in patients taking anti-adrenergic drugs (e.g., beta-blockers, clonidine, guanethidine, and reserpine). 

Important Safety Information for MERILOG SoloStar
MERILOG SoloStar is a disposable single-patient-use prefilled insulin pen. To help ensure an accurate dose each time, patients should follow the steps in the Instruction Leaflet accompanying the pen; otherwise, they may not get the correct amount of insulin, which may affect their blood glucose levels.

Click here for full Prescribing information for MERILOG.
Click here for information on Sharps Medical Waste Disposal.
Click here to learn more about Sanofi's commitment to fighting counterfeit drugs.

Indication

MERILOG is a rapid-acting human insulin analog indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus.

Important Safety Information

Indication

NovoLog is a registered trademark of Novo Nordisk A/S MAT-US-2502959-v2.0-11/2025

Back to top
Back to top
SitemapLegal NoticePrivacy PolicyCookie PolicyDo Not Sell or Share My Personal InformationContactAccessibility Statement
© 2025 Sanofi. All rights reserved.